Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Preferred Stock Liabilities: 2023

Historic Preferred Stock Liabilities for CG Oncology (CGON) over the last 1 years, with Dec 2023 value amounting to $120.0 million.

  • CG Oncology's Preferred Stock Liabilities was N/A to $120.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $120.0 million, marking a year-over-year change of. This contributed to the annual value of $120.0 million for FY2023, which is N/A change from last year.
  • According to the latest figures from FY2023, CG Oncology's Preferred Stock Liabilities is $120.0 million.
  • CG Oncology's Preferred Stock Liabilities' 5-year high stood at $120.0 million during FY2023, with a 5-year trough of $120.0 million in FY2023.
  • In the last 1 years, CG Oncology's Preferred Stock Liabilities had a median value of $120.0 million in 2023 and averaged $120.0 million.